Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of JKN23051 in inadequately controlled moderate-to-severe asthma
CTR20243291Phase 2Active
- Sponsor
- Langyu Pharmaceutical Technology
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JKN23051 in asthma, sponsored by Langyu Pharmaceutical Technology. Started Sep 2024; status: active.
02
Drugs
JKN23051
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20243291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243291.